AU2019336667B2 - Chronic nightly dosing of lasmiditan for migraine prevention - Google Patents
Chronic nightly dosing of lasmiditan for migraine prevention Download PDFInfo
- Publication number
- AU2019336667B2 AU2019336667B2 AU2019336667A AU2019336667A AU2019336667B2 AU 2019336667 B2 AU2019336667 B2 AU 2019336667B2 AU 2019336667 A AU2019336667 A AU 2019336667A AU 2019336667 A AU2019336667 A AU 2019336667A AU 2019336667 B2 AU2019336667 B2 AU 2019336667B2
- Authority
- AU
- Australia
- Prior art keywords
- migraine
- lasmiditan
- patient
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022291568A AU2022291568A1 (en) | 2018-09-04 | 2022-12-22 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
| AU2025201479A AU2025201479A1 (en) | 2018-09-04 | 2025-02-28 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726585P | 2018-09-04 | 2018-09-04 | |
| US62/726,585 | 2018-09-04 | ||
| PCT/US2019/049340 WO2020051137A1 (en) | 2018-09-04 | 2019-09-03 | Chronic nightly dosing of lasmiditan for migraine prevention |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022291568A Division AU2022291568A1 (en) | 2018-09-04 | 2022-12-22 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019336667A1 AU2019336667A1 (en) | 2021-03-11 |
| AU2019336667B2 true AU2019336667B2 (en) | 2022-09-29 |
Family
ID=68051892
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019336667A Ceased AU2019336667B2 (en) | 2018-09-04 | 2019-09-03 | Chronic nightly dosing of lasmiditan for migraine prevention |
| AU2022291568A Abandoned AU2022291568A1 (en) | 2018-09-04 | 2022-12-22 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
| AU2025201479A Abandoned AU2025201479A1 (en) | 2018-09-04 | 2025-02-28 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022291568A Abandoned AU2022291568A1 (en) | 2018-09-04 | 2022-12-22 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
| AU2025201479A Abandoned AU2025201479A1 (en) | 2018-09-04 | 2025-02-28 | Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention |
Country Status (36)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2413933T5 (pl) | 2009-04-02 | 2021-10-18 | Colucid Pharmaceuticals, Inc. | 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną |
| JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｇｒｐ活性化合物の錠剤製剤 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN116390712A (zh) * | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
| US5360735A (en) | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
| US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| US5698571A (en) | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| NZ305166A (en) | 1995-03-20 | 1998-12-23 | Lilly Co Eli | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments |
| US5942536A (en) | 1995-10-10 | 1999-08-24 | Eli Lilly And Company | N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists |
| US5708187A (en) | 1996-06-27 | 1998-01-13 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists |
| BR9711273A (pt) | 1996-08-28 | 1999-08-17 | Lilly Co Eli | 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos |
| AU4652697A (en) | 1996-10-08 | 1998-05-05 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
| ZA979961B (en) | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| EP0875513A1 (en) | 1997-04-14 | 1998-11-04 | Eli Lilly And Company | Substituted heteroaromatic 5-HT 1F agonists |
| ID23053A (id) | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| US5905084A (en) | 1997-11-14 | 1999-05-18 | Eli Lilly And Company | 5-HTIF -agonists effective in treating migraine |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| AU4961499A (en) | 1998-06-26 | 2000-01-17 | Eli Lilly And Company | 5-HT1f agonists |
| JP2002519348A (ja) | 1998-06-30 | 2002-07-02 | イーライ・リリー・アンド・カンパニー | ５−ｈｔ１ｆアゴニスト |
| US6608079B1 (en) | 1998-12-11 | 2003-08-19 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
| US6777428B1 (en) | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
| DE60036924T2 (de) | 1999-02-10 | 2008-08-14 | Eli Lilly And Co., Indianapolis | 5-ht1f agonisten |
| AU3354000A (en) | 1999-02-26 | 2000-09-14 | Eli Lilly And Company | 5-ht1f agonists |
| WO2002006196A1 (en) | 2000-07-13 | 2002-01-24 | Merck Patent Gmbh | Chiral compounds i |
| US6650463B2 (en) | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
| WO2003000245A1 (en) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| AU2003295782A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers |
| GB0308186D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| MXPA05011223A (es) | 2003-04-18 | 2006-01-26 | Lilly Co Eli | Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif. |
| WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| AU2005311251A1 (en) | 2004-12-01 | 2006-06-08 | Devgen Nv | 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family |
| KR20060067738A (ko) | 2004-12-15 | 2006-06-20 | 주식회사 대웅제약 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물 |
| US20060178349A1 (en) | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| KR100976063B1 (ko) | 2007-03-16 | 2010-08-17 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법 |
| PL2413933T5 (pl) * | 2009-04-02 | 2021-10-18 | Colucid Pharmaceuticals, Inc. | 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną |
| US8697876B2 (en) * | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| KR20190075130A (ko) | 2016-12-06 | 2019-06-28 | 코루시드 파마슈티컬즈 인코포레이티드 | 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
-
2019
- 2019-09-02 TW TW108131567A patent/TWI826514B/zh active
- 2019-09-03 AU AU2019336667A patent/AU2019336667B2/en not_active Ceased
- 2019-09-03 PT PT197735830T patent/PT3846810T/pt unknown
- 2019-09-03 EP EP23195738.2A patent/EP4279132A3/en active Pending
- 2019-09-03 RS RS20231107A patent/RS64857B1/sr unknown
- 2019-09-03 MD MDE20210640T patent/MD3846810T2/ro unknown
- 2019-09-03 HU HUE19773583A patent/HUE064519T2/hu unknown
- 2019-09-03 CN CN201980055464.3A patent/CN112638383A/zh active Pending
- 2019-09-03 DK DK19773583.0T patent/DK3846810T3/da active
- 2019-09-03 EP EP19773583.0A patent/EP3846810B1/en active Active
- 2019-09-03 SG SG11202101530PA patent/SG11202101530PA/en unknown
- 2019-09-03 LT LTEPPCT/US2019/049340T patent/LT3846810T/lt unknown
- 2019-09-03 SI SI201930647T patent/SI3846810T1/sl unknown
- 2019-09-03 BR BR112021002945-1A patent/BR112021002945A2/pt unknown
- 2019-09-03 UA UAA202100630A patent/UA129587C2/uk unknown
- 2019-09-03 EA EA202190440A patent/EA202190440A1/ru unknown
- 2019-09-03 PE PE2021000286A patent/PE20211599A1/es unknown
- 2019-09-03 FI FIEP19773583.0T patent/FI3846810T3/fi active
- 2019-09-03 IL IL281208A patent/IL281208B2/en unknown
- 2019-09-03 MY MYPI2021001043A patent/MY199662A/en unknown
- 2019-09-03 JP JP2021512380A patent/JP7321256B2/ja active Active
- 2019-09-03 CR CR20210126A patent/CR20210126A/es unknown
- 2019-09-03 MX MX2021002474A patent/MX2021002474A/es unknown
- 2019-09-03 ES ES19773583T patent/ES2967665T3/es active Active
- 2019-09-03 MA MA53551A patent/MA53551B1/fr unknown
- 2019-09-03 WO PCT/US2019/049340 patent/WO2020051137A1/en not_active Ceased
- 2019-09-03 PL PL19773583.0T patent/PL3846810T3/pl unknown
- 2019-09-03 HR HRP20231587TT patent/HRP20231587T1/hr unknown
- 2019-09-03 US US17/271,950 patent/US12138254B2/en active Active
- 2019-09-03 KR KR1020217005977A patent/KR102649644B1/ko active Active
-
2021
- 2021-01-29 ZA ZA2021/00666A patent/ZA202100666B/en unknown
- 2021-02-25 JO JOJO/P/2021/0033A patent/JOP20210033B1/ar active
- 2021-03-01 CO CONC2021/0002766A patent/CO2021002766A2/es unknown
- 2021-03-02 DO DO2021000039A patent/DOP2021000039A/es unknown
- 2021-03-02 PH PH12021550448A patent/PH12021550448A1/en unknown
- 2021-03-03 CL CL2021000529A patent/CL2021000529A1/es unknown
- 2021-03-04 EC ECSENADI202115491A patent/ECSP21015491A/es unknown
-
2022
- 2022-12-22 AU AU2022291568A patent/AU2022291568A1/en not_active Abandoned
-
2023
- 2023-07-25 JP JP2023120471A patent/JP7543497B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201479A patent/AU2025201479A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| Anonymous, "Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment", ClinicalTrials.gov, (2009-09-10), URL: https://web.archive.org/web/2009-09-10220814/clinicaltrials.gov/ct2/show/NCT00883051, (2018-09-20) * |
| JESSICA C OSWALD ET AL, JOURNAL OF PAIN RESEARCH, GB, (2018-10-08), Volume 11, doi:10.2147/JPR.S152216, ISSN 1178-7090, pages 2221 - 2227, [T] 1-13 * |
| MARKUS FÄRKKILÄ ET AL, LANCET NEUROLOGY, GB, (2012-05-01), vol. 11, no. 5, doi:10.1016/S1474-4422(12)70047-9, ISSN 1474-4422, pages 405 - 413 * |
| PETER J GOADSBY ET AL, "Migraine - Current understanding and Treatment", N ENGL. J. MED, (2002-01-24), vol. 346, no. 4, doi:10.1056/NEJMra010917, pages 257 - 270 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019336667B2 (en) | Chronic nightly dosing of lasmiditan for migraine prevention | |
| Fava et al. | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. | |
| Johnson et al. | Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence | |
| Davidson et al. | Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder | |
| EP3340971B1 (en) | Methods of treating lennox-gastaut syndrome using fenfluramine | |
| Ruggiero et al. | Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis | |
| US7462595B2 (en) | Methods for treating cancer-related fatigue | |
| CA3062247A1 (en) | Methods of treating doose syndrome using fenfluramine | |
| Hornig-Rohan et al. | Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression | |
| Spreckelmeyer et al. | Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [18F] fallypride positron emission tomography study | |
| CN110214146A (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| CA3111205C (en) | Chronic nightly dosing of lasmiditan for migraine prevention | |
| HK40045255A (en) | Chronic nightly dosing of lasmiditan for migraine prevention | |
| HK40045255B (en) | Chronic nightly dosing of lasmiditan for migraine prevention | |
| Yeo et al. | Oral agents for the management of agitation and agitated delirium in critically ill patients | |
| EA046122B1 (ru) | Длительное введение ласмидитана на ночь для профилактики мигрени | |
| Extein et al. | Antidepressants: predicting response/maximizing efficacy | |
| Hardan | Neurobiology of Autism and Other Pervasive Developmental Disorders: Basic Mechanisms and Therapeutic Interventions | |
| Reisner et al. | Reboxetine (PNU-155950E) Versus Placebo and Fluoxetine in a Controlled, Randomized, Double-Blind, Multicenter Study of Treatment in Major Depressive Disorders | |
| Froeschke et al. | Reboxetine (PNU-155950E) vs. placebo in the treatment of major depressive disorder resistant to fluoxetine | |
| Brierley-Bowers | Child and Adolescent Program of the 41st Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, Arizona, May 28–31, 2001 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |